February 15, 2018 - By Marguerite Chambers

The stock of MEDIFOCUS INCORPORATED (OTCMKTS:MDFZF) registered a decrease of 43.48% in short interest. MDFZF’s total short interest was 3,900 shares in February as published by FINRA. Its down 43.48% from 6,900 shares, reported previously. With 31,900 shares average volume, it will take short sellers 0 days to cover their MDFZF’s short positions.

It closed at $0.0342 lastly. It is down 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Medifocus Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada and the United States. The company has market cap of $6.33 million. The firm owns technology platforms, including Endo-thermotherapy platform, a catheter focused heat technology platform that utilizes natural body openings to deliver microwave thermotherapy to the diseased sites; and Adaptive Phased Array Microwave Focusing platform, which directs focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. It currently has negative earnings. It also offers Prolieve Thermodilatation system, a medical device based on endo-thermotherapy for the treatment of benign prostatic hyperplasia.

More important recent Medifocus Inc. (OTCMKTS:MDFZF) news were published by: which released: “Research and Markets: Leading 100 Medical Devices Companies of USA/Canada 2015” on March 23, 2015, also published article titled: “Medifocus Inc.”, published: “PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors” on October 10, 2017. More interesting news about Medifocus Inc. (OTCMKTS:MDFZF) was released by: and their article: “Medifocus, Inc. Expands Its Reach into the Israeli Market with Amos Gazit Ltd …” with publication date: January 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.